CAS:1239875-86-5SGI-7079

您的位置 : 首页 / Protein Tyrosine Kinase/RTK / TAM Receptor / SGI-7079

SGI-7079 Cat No. FB00445Cas No. 1239875-86-5

SGI-7079, a selective Axl inhibitor, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.1952 mL
- 10.9762 mL
- 21.9525 mL
- 5 mM
- 0.4390 mL
- 2.1952 mL
- 4.3905 mL
- 10 mM
- 0.2195 mL
- 1.0976 mL
- 2.1952 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

1239875-86-5

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C26H26FN7

运输

蓝冰

分子量

455.53

别名

溶解度

DMSO	91.0 mg/mL (199.8 mM)
Water	Insoluble
Ethanol	Insoluble

动物实验配方

靶点数据

生物活性

描述The AXL protein, classified as a RTK (Receptor tyrosine kinase), belongs to the TAM (TYRO3, AXL, and MER) subfamily. Overexpression or overactivation of the AXL has been correlated with the promotion of multiple tumorigenic processes. SGI-7079 is a relatively potent AXL inhibitor (IC₅₀ = 58 nM, in cell-free assays) in preclinical development. It inhibits GAS6-stimulated AXL signaling in inflammatory breast cancer cells (IC₅₀ < 1 μM), resulting in decreased cell proliferation and invasion^[3]. Mesenchymal cell lines expressing Axl were highly sensitive to SGI-7079 alone. In a mouse xenograft model of NSCLC (non-small cell lung cancer), SGI-7079 inhibited tumor growth in a dose dependent manner, and at the maximum dose, inhibited tumor growth by 67%, compared to control. Notably, SGI-7079 + erlotinib (25/100 mg/kg) reduced the tumor growth by 82%^[4].